Big Pharma — Biogen

Biogen's Alzheimer's drug aducanumab, if approved, may face extra hurdles, slow sales ramp: analysts Even if it were approved by the FDA, Biogen's controversial Alzheimer's drug aducanumab could suffer a slow sales ramp thanks to physician concerns, payer pushback and limitation of healthcare infrastructure, analysts said. (Biogen) Just a handful of days are left until patients, families, investors and Biogen executives will know the next chapter for the company’s controversial Alzheimer’s disease drug candidate aducanumab. But even if the drug scores its coveted FDA nod, a quick rollout is no sure thing, analysts say. Confusion among physicians, resistance from payers and even the need for...